Abstract
Objective The antisense oligonucleotide nusinersen (spinraza) regulates splicing of the survival motor neuron 2 (SMN2) messenger RNA to increase SMN protein expression and has improved ventilator free survival and motor function outcomes in infantile onset forms of SMA, treated early in the course of the disease. However, the response in later onset forms of SMA is highly variable and dependent on symptom severity and disease duration at treatment initiation. Therefore, we aimed to identify novel noninvasive biomarkers that could predict the response to nusinersen in type II and III SMA patients.
Methods 34 SMA patients were included. We applied next-generation sequencing to identify microRNAs in the cerebrospinal fluid (CSF) as candidate biomarkers predicting response to nusinersen. Hammersmith Functional Motor Scale Expanded (HFMSE), was conducted at baseline and 6 months post initiation of nusinersen therapy to assess motor function. Patients changing by ≥ 3 or ≤0 points in the HFMSE total score were considered as responders or non-responders, respectively.
Results Lower baseline levels of two muscle microRNAs (miR-206 and miR-133), alone or in combination, predicted the pre-determined clinical response to nusinersen after 6 months therapy. Moreover, miR-206 levels were inversely correlated with the HFMSE score.
Conclusions Lower miR-206 and miR-133 in the CSF predict more robust clinical response to nusinersen treatment in later onset SMA patients. These novel findings have high clinical relevance for identifying early treatment response to nusinsersen in later onset SMA patients and call to test the ability of miRNAs to predict more sustained long-term benefit.
Competing Interest Statement
CRRA and KJS are inventors on a patent filed by Mass General Brigham that describes genome-engineering technologies to treat SMA. KJS has received clinical trial funding from AveXis/Novartis and Biogen. She has received speaker fees from Biogen and has served on scientific advisory boards for AveXis, Biogen, Roche/Genentech. SA has received clinical trial funding from AveXis/Novartis Gene Therapies and Biogen and has served on scientific advisory boards for AveXis/Novartis Gene Therapies.
Funding Statement
Research at Hornstein lab is supported by CReATe consortium and ALSA (program: Prognostic value of miRNAs in biofluids from ALS patients), RADALA Foundation, AFM Telethon (20576), Weizmann Brazil Center for Research on Neurodegeneration at Weizmann Institute of Science, the Minerva Foundation with funding from the Federal German Ministry for Education and Research, ISF Legacy Heritage Fund 828/17, Israel Science Foundation 135/16, 392/21, 393/21, 3497/21. Target ALS 118945, Thierry Latran Foundation for ALS Research. the European Research Council under the European Unions Seventh Framework Programme (FP7/2007 2013)/ERC grant agreement number 617351, ERA-Net for Research Programmes on Rare Diseases (eRARE FP7) via Israel Ministry of Health, Dr. Sydney Brenner and friends, Edward and Janie Moravitz, A. Alfred Taubman through IsrALS, Yeda-Sela, Yeda CEO, Israel Ministry of Trade and Industry, Y. Leon Benoziyo Institute for Molecular Medicine, Kekst Family Institute for Medical Genetics, David and Fela Shapell Family Center for Genetic Disorders Research, Crown Human Genome Center, Nathan, Shirley, Philip and Charlene Vener New Scientist Fund, Julius and Ray Charlestein Foundation, Fraida Foundation, Wolfson Family Charitable Trust, Adelis Foundation, Merck (United Kingdom), M. Halphen, and Estates of F. Sherr, L. Asseof, L. Fulop. NSY was supported by the Israeli Council for Higher Education (CHE) via the Weizmann Data Science Research Center. IM was supported by Teva Pharmaceutical Industries Ltd. as part of the Israeli National Network of Excellence in Neuroscience (NNE, fellowship 117941). CRRA was funded by MGH Executive Committee on Research. KJS was funded by NIH NICHD R01HD054599, NIH NINDS R21NS108015, Biogen, AveXis and Cure SMA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB Weizmann
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos